Nexiclon Xr

Hot Flashes, Smoke, clonidine suppression test + 15 more

Treatment

20 Active Studies for Nexiclon Xr

What is Nexiclon Xr

Clonidine

The Generic name of this drug

Treatment Summary

Clonidine is a drug used to treat high blood pressure, severe pain, and Attention Deficit Hyperactivity Disorder (ADHD). It works by targeting alpha-2 adrenoceptors in the body. Clonidine was approved by the FDA in 1974 and is available under the brand name Catapres.

Catapres

is the brand name

image of different drug pills on a surface

Nexiclon Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Catapres

Clonidine

1974

447

Effectiveness

How Nexiclon Xr Affects Patients

Clonidine works by activating certain receptors in the body that help to lower blood pressure, cause drowsiness, and make nerves less sensitive. It usually needs to be taken twice a day and the usual dose is between 0.1mg and 2.4mg per day.

How Nexiclon Xr works in the body

Clonidine is a type of drug that works on the alpha-2 adrenoceptor, a kind of protein in your body. When clonidine binds to this receptor, it causes changes in the cell that stop it from functioning as normal. This leads to a decrease in nerve activity, which can reduce pain signals and create a hypnotic effect. It can also affect the way your body regulates blood pressure.

When to interrupt dosage

The advised dosage of Nexiclon Xr is contingent upon the diagnosed disorder, including methadone, diabetic diarrhea and Hypertensive disease. The measure of dosage also depends upon the technique of delivery (e.g. Oral or Tablet) featured in the table hereunder.

Condition

Dosage

Administration

Hypertensive disease

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Pheochromocytoma

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Tourette Syndrome

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Disease

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Attention Deficit and Disruptive Behavior Disorders

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Smoke

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

clonidine suppression test

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

clozapine

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

methadone

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Cancer Pain

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

growth hormone stimulation test

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

diabetic diarrhea

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Hot flashes

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Neuralgia, Postherpetic

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Human Growth Hormone Deficiency

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Attention Deficit Hyperactivity Disorder

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Smoking Cessation

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Hot Flashes

, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg

, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release - Oral, For suspension, extended release, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release - Oral, Suspension, extended release

Warnings

Nexiclon Xr has five contraindications, so it should not be employed when afflicted with any of the conditions noted in the table below.

Nexiclon Xr Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

administration above the C4 dermatome

Do Not Combine

Communicable Diseases

Do Not Combine

bleeding diathesis

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Clonidine may interact with Pulse Frequency

There are 20 known major drug interactions with Nexiclon Xr.

Common Nexiclon Xr Drug Interactions

Drug Name

Risk Level

Description

1,2-Benzodiazepine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 1,2-Benzodiazepine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 4-Bromo-2,5-dimethoxyamphetamine.

4-Methoxyamphetamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 4-Methoxyamphetamine.

5-methoxy-N,N-dimethyltryptamine

Major

The risk or severity of sedation can be increased when Clonidine is combined with 5-methoxy-N,N-dimethyltryptamine.

Nexiclon Xr Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats is 126 mg/kg. In children, women, and men, the lowest toxic dose is 70µg/kg, 126µg/kg, and 69µg/kg respectively. An overdose of this drug can cause high or low blood pressure, slow heart rate, difficulty breathing, low body temperature, drowsiness, decreased reflexes, weakness, irritability, and constricted pupils. Severe overdoses can also cause heart rhythm problems, apnea, coma, and seizures. Vomiting is not recommended due to CNS depression, but a gastric lavage

image of a doctor in a lab doing drug, clinical research

Nexiclon Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Nexiclon Xr?

231 active trials are in progress to assess the potential of Nexiclon Xr for Smoking Cessation, Menopausal symptom relief and severe Cancer pain mitigation.

Condition

Clinical Trials

Trial Phases

Smoking Cessation

104 Actively Recruiting

Early Phase 1, Phase 4, Not Applicable, Phase 3, Phase 2, Phase 1

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

clonidine suppression test

0 Actively Recruiting

growth hormone stimulation test

0 Actively Recruiting

diabetic diarrhea

0 Actively Recruiting

Tourette Syndrome

0 Actively Recruiting

Neuralgia, Postherpetic

0 Actively Recruiting

Human Growth Hormone Deficiency

4 Actively Recruiting

Phase 2, Phase 4, Phase 3

Hot Flashes

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Cancer Pain

0 Actively Recruiting

Disease

6 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

methadone

0 Actively Recruiting

Attention Deficit and Disruptive Behavior Disorders

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

clozapine

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Pheochromocytoma

0 Actively Recruiting

Smoke

0 Actively Recruiting

Nexiclon Xr Reviews: What are patients saying about Nexiclon Xr?

1

Patient Review

1/18/2012

Nexiclon Xr for Symptoms from Stopping Treatment with Opioid Drugs

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nexiclon xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug clonidine used for?

"This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure.

Clonidine is used to treat high blood pressure by decreasing the amount of work the heart and arteries have to do. If left untreated, high blood pressure can damage the blood vessels in the brain, heart, and kidneys, which can lead to a stroke, heart failure, or kidney failure."

Answered by AI

What happens if you take too much clonidine?

"If you take too much clonidine, your blood pressure or heart rate could drop dangerously low, you could become deeply sedated, and you might have trouble breathing normally."

Answered by AI

Can you stop clonidine abruptly?

"Do not interrupt or stop taking this medicine without first checking with your doctor. Your doctor may want you to gradually reduce the amount you are taking before stopping it completely. Your blood pressure may become worse when the medicine is stopped suddenly, which can cause serious side effects."

Answered by AI

Clinical Trials for Nexiclon Xr

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Nexiclon Xr clinical trials?

We made a collection of clinical trials featuring Nexiclon Xr, we think they might fit your search criteria.
Go to Trials
Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Nexiclon Xr clinical trials?

We made a collection of clinical trials featuring Nexiclon Xr, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Have you considered Nexiclon Xr clinical trials?

We made a collection of clinical trials featuring Nexiclon Xr, we think they might fit your search criteria.
Go to Trials